<DOC>
	<DOCNO>NCT00356941</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Oxaliplatin docetaxel may make tumor cell sensitive radiation therapy . Giving oxaliplatin docetaxel together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose oxaliplatin give together docetaxel radiation therapy treat patient unresectable stage II stage III recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Oxaliplatin , Docetaxel , Radiation Therapy Treating Patients With Unresectable Stage II/III Recurrent NSCLC</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose oxaliplatin give docetaxel thoracic radiotherapy patient unresectable stage II , IIIA , IIIB recurrent non-small cell lung cancer . Secondary - Determine dose-limiting toxicity regimen patient . - Determine objective tumor response patient treat regimen . OUTLINE : This dose-escalation study oxaliplatin . - Induction therapy : Patients undergo radiotherapy day day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Patients also receive docetaxel intravenous ( IV ) 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 oxaliplatin IV 2-4 hour day 2 , 9 , 16 , 23 , 30 , 37 , 44 . Patients stable respond disease proceed consolidation therapy . Cohorts 6 patient receive escalate dos oxaliplatin induction therapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . - Consolidation therapy : Beginning 3 week completion induction therapy , patient receive consolidation therapy comprise docetaxel IV 1 hour immediately follow oxaliplatin IV 2-4 hour day 1 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 3 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Diagnosis nonsmall cell lung cancer ( NSCLC ) meet 1 follow criterion : Medically inoperable unresectable stage II , IIIA , IIIB disease Postresection intrathoracic tumor recurrence Measurable disease compute tomography ( CT ) scan No evidence small cell histology No significant pleural effusion chest xray malignant pleural effusion cytology No metastatic disease Eastern Cooperative Oncology Group ( ECOG ) ( Zubrod ) performance status 01 Absolute granulocyte count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL Bilirubin ≤ 1.5 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) ≤ 1.5 time upper limit normal ( unless abnormality cause documented benign disease ) Creatinine ≤ 1.5 mg/dL Weight loss ≤ 10 % within past 3 month Forced expiratory volume ( FEV ) 1 ≥ 1,000 cc Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Synchronous ( except nonmelanomatous skin cancer ) prior invasive malignancy , unless disease free &gt; 3 year Myocardial infarction within past 6 month Symptomatic heart disease , include follow : Angina Congestive heart failure Uncontrolled arrhythmia Active infection fever ≥ 38.5°C within past 3 day Known hypersensitivity component oxaliplatin docetaxel Prior thoracic neck radiotherapy Prior docetaxel oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>